

January 19, 2023

To,
Department of Corporate Services,
BSE Limited
Ground Floor, P. J. Towers,
Dalal Street,
Mumbai – 400001

Scrip Code: 541735

Sub: Intimation of receipt of Work Order/Letter of Intent

Dear Sir/Madam,

With reference to the Intimation letter dated 18th January, 2023, and as per the email received from BSE today i.e. 19.01.2023 requiring Additional Details under SEBI Circular dated September 09, 2015. We wish to submit the receipt of work orders worth INR 52 Crores (Fifty Two Crores Rupees Only) in Institutional and Industrial categories with additional details as per SEBI Circular dated September 09, 2015;

1. Receipt of an order for construction of 165 beds hospital at Dahod:

The Company has entered into agreement with Sarthak Multispecialty Hospital LLP Dahod, Gujarat for the execution of Hospital with the capacity up to 165 beds to be constructed at katwara, Indore Highway Dahod, Gujarat. This facility is spread over 80,000 Sq, ft area which is second largest facility of Dahod. This project will also cater to secondary care services on cost effective model for middle strata of the population.

The project is expected to commence operations from April, 2023.

2. Setting up of the Laboratory in South Sudan:

The Company has entered into Joint Venture Agreement with Tamy General Trading Co. LTD. The Joint Venture will conduct its business under the name of South Sudan Analytical Laboratory. The Joint Venture shall be formed for the purpose of setting up Government approved analytical testing facilities for pharmaceutical formulation, Medical devices, Mineral Water, Gloves and Condoms.

The project is expected to commence operations from April, 2023.

CIN: L74110GJ2013PLC075393



Declaration as per SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015 is attached at Annexure A.

You are requested to take the same on your record.

Thanking you,

For, Vivanta Industries Limited

Sweta Sandip Digitally signed by Sweta Sandip Prajapati Date: 2023.01.19 16.06.07 +05'30'

Sweta Prajapati

Company Secretary & Compliance Officer

Membership No.: A66245



Annexure- A Declaration as per SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015 are as under:

S.No.	Particulars	Details of Projects No.
a	Name of the entity awarding the order(s)/contract(s);	Sarthak Multispecialty Hospital LLP
b	Significant terms and conditions of order (s)/contract (s) awarded in brief	To Construct Hospital with the capacity up to 165 beds at katwara, Indore Highway Dahod, Gujarat. This facility is spread over 80,000 Sq. ft area which is second largest facility of Dahod
С	Whether order(s) / contract(s) have been awarded by domestic/international entity;	Domestic
d	Nature of order(s) I contract(s);	Hospital turnkey project spreading over 80,000 Sq, ft area with capacity of up to 165 beds.
е	Whether domestic or international;	Domestic
f	Time period by which the order(s)/contract(s) is to be executed;	April 2023
g	Broad consideration or size of the order(s)/contract(s);	The Project cost for Phase I is 28 Crores
h	Whether the promoter/ promoter group / group companies have any interest in the entity that awarded the order(s)/contract(s)? If yes, nature of interest and details thereof;	No
i	Whether the order(s)/contract(s) would fall within related party transactions? If yes, whether the same is done at "arm's length".	No



Annexure- A

Declaration as per SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015 are as under:

S.No.	Particulars	Details of Projects No.
a	Name of the entity awarding the	Drugs & Food Control Authority, JUBA,
	order(s)/contract(s);	South Sudan.
b	Significant terms and conditions of order (s)/contract (s) awarded in brief	A Joint Venture shall be formed with Tamy General Trading Co. LTD under the name of South Sudan Analytical Laboratory for the purpose of setting up Government approved analytical testing facilities
С	Whether order(s) / contract(s) have been awarded by domestic/international entity;	International
d	Nature of order(s) I contract(s);	Setting up Government approved analytical testing facilities for pharmaceutical formulation, Medical devices, Mineral Water, Gloves and Condoms.
e	Whether domestic or international;	International
f	Time period by which the order(s)/contract(s) is to be executed;	April 2023
g	Broad consideration or size of the order(s)/contract(s);	The Project cost for Phase I is 24 Crores
h	Whether the promoter/ promoter group / group companies have any interest in the entity that awarded the order(s)/contract(s)? If yes, nature of interest and details thereof;	No
i	Whether the order(s)/contract(s) would fall within related party transactions? If yes, whether the same is done at "arm's length".	No